Abstract
Atherosclerosis is a multifactorial, lipoprotein-driven condition that leads to plaque formation within the arterial tree, leading to subsequent arterial stenosis and thrombosis that accounts for a large burden of cardiovascular morbidity and mortality globally. Atherosclerosis of the lower extremities is called peripheral artery disease and is a major cause of loss in mobility, amputation, and critical limb ischemia. Peripheral artery disease is a common condition with a gamut of clinical manifestations that affects an estimated 10 million people in the United States of America and 200 million people worldwide. The role of apolipoprotein B-containing lipoproteins, such as LDL and remnant lipoproteins in the development and progression of atherosclerosis, is well-established. The focus of this paper is to review existing data on lipid-lowering therapies in lower extremity atherosclerotic peripheral artery disease.
Original language | English |
---|---|
Article number | 4872 |
Journal | Journal of Clinical Medicine |
Volume | 11 |
Issue number | 16 |
DOIs | |
Publication status | Published - Aug 2022 |
Externally published | Yes |
Keywords
- PCSK9 inhibitors
- amputation
- atherosclerosis
- critical limb ischemia
- icosapent ethyl
- inclisiran
- intermittent claudication
- lipoprotein
- peripheral artery disease
- statin